App-Quantinova.ai

Dynamic testing of positive and negative biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.

Wushuang Du - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

A single-institution study of renal outcomes in patients receiving checkpoint inhibitors.

Sarah Mushtaq - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Retrospective review of immune checkpoint inhibitor therapy (ICI) at the Michael E. DeBakey VA Medical Center Cancer Center (MEDVAMCCC).

Jan Ole Kemnade - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.

Dejan Juric - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

A longitudinal retrospective case series of the real-world toxicities encountered among cancer patients receiving anti-PD-L1 checkpoint inhibitor immunotherapy.

Anastasios L. Boutis - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Retronectin and anti-CD3 monoclonal antibody actived T cell combined anti-PD-1 therapy in heavy-treated renal cell cancer.

Ling-Di Zhao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Nivolumab

Changes of microbiome profile during nivolumab treatment in NSCLC patients.

Andrea Botticelli - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Monitoring of thyroid function test abnormalities in cancer patients undergoing immune checkpoint inhibitor therapy in a community based cancer center.

Mehmet Sitki Copur - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Anatomic site of metastases can influence response to nivolumab in NSCLC patients.

Andrea Botticelli - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Antibiotic use and overall survival in lung cancer patients receiving nivolumab.

Tien Phuc Do - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Mapping PD-1 inhibitors side effects using patient-reported outcomes (PRO) generated by a digital patient-powered network (PPN).

Daniel A. Vorobiof - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Concurrent nivolumab and radiotherapy to improve outcomes for patients with metastatic lung and renal cancers.

Jawaher Ansari - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Nivolumab

Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.

Kushal Gupta - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Adoption rates of immune checkpoint inhibitors in real world oncology practice.

Jennifer O. Nwankwo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Novel anti-PD-1 antibodies not acting through PD-1/pdl-1 blockade that enhance tumor clearance.

Craig Fenwick - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).

Neil J. Shah - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Impact of anti-infectious and corticosteroids on immunotherapy: Nivolumab and pembrozilumab follow-up in a French study.

Jean-Philippe Metges - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Immunological effect of hydrogen gas.

Junji Akagi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.

Sassan Ostvar - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Initial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC).

Ping Gu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Filters

2342 Abstracts